1. Introduction

The Central Drugs Standard Control Organisation (CDSCO), which functions under the Ministry of Health and Family Welfare, is the national regulator responsible for approving new drugs, medical devices, clinical trials, imports, and manufacturing permissions.

Over the past few years, CDSCO has attempted to digitise approvals through multiple online portals. However, industry stakeholders have repeatedly reported technical glitches, slow processing, repeated document submissions, and lack of transparency in application status. These inefficiencies have often delayed critical approvals for manufacturers and exporters.

To address these issues, CDSCO has now initiated plans for a comprehensive digital overhaul by inviting bids for the creation of the Digital Drugs Regulatory System (DDRS). This proposed platform aims to create a unified, end-to-end online regulatory ecosystem for drugs, medical devices, and related products, potentially transforming India’s approval framework in the same way digital reforms changed taxation and payments systems.

2. Origin and Intent

India’s current drug regulatory system evolved in phases, with separate digital platforms introduced for different functions rather than one integrated mechanism. As a result, companies today often need to navigate multiple portals depending on the nature of their application.

Among the existing systems is the Online National Drugs Licensing System (ONDLS), designed as a single-window interface for state regulators to process manufacturing and sales licences. It also handles export-related certificates such as Good Manufacturing Practice (GMP) compliance documents and product registration certificates required by foreign governments.

Similarly, the Sugam portal manages applications related to imports, clinical trials, test licences, and new drug approvals, while MD Online focuses on medical devices. Though these portals represented progress toward digitisation, they also created duplication and confusion.

Industry bodies have noted that approvals which should ideally be completed within 45 days often take several months due to technical bottlenecks, portal downtime, and back-and-forth communication. Rajiv Nath, Forum Coordinator of the Association of Indian Medical Device Industry (AiMED), highlighted issues such as fragmented portals, inconsistent document uploads, lack of real-time tracking, weak integration with state authorities, and frequent delays caused by system outages.

3. Key Amendments 

According to the proposal, DDRS will replace the current patchwork of regulatory portals with a single digital platform covering all categories regulated by CDSCO and state licensing authorities.

This includes:

• Pharmaceuticals 
• Biological products and vaccines 
• Medical devices 
• Cosmetics 
• Veterinary medicines 
• Emerging therapies and advanced healthcare products 

The new system is expected to offer a common interface for applications, approvals, renewals, inspections, compliance filings, and certifications.

CDSCO has described DDRS as a form of Digital Public Infrastructure (DPI) for healthcare regulation. This comparison is significant. India’s Aadhaar system transformed identity verification, while the Unified Payments Interface (UPI) revolutionised digital payments by creating a seamless interoperable platform. DDRS is intended to bring similar efficiency and interoperability to drug regulation.

The platform is also expected to use automated workflows, digital signatures, document repositories, dashboard-based monitoring, and timeline-based processing to reduce manual intervention.

4. Impact

If implemented effectively, DDRS could significantly improve the ease of doing business for India’s healthcare manufacturing sector. Under the proposed model, all approvals—from manufacturing licences and import clearances to export certifications—would be routed through one platform.

Instead of submitting the same information repeatedly to different agencies, companies would be able to file a single application, with data automatically shared across linked systems such as:

• Goods and Services Tax Network (GSTN) 
• Customs authorities 
• Indian Council of Medical Research (ICMR) 
• State drug regulators 

This integration could reduce compliance burdens, minimise paperwork, and improve turnaround times.

Another major reform is transparency. Applicants would be able to track each stage of approval online, including timelines, pending queries, and responsible authorities. This would help reduce uncertainty and improve accountability.

The proposal also envisions digital traceability across the supply chain—from manufacturing units to distributors, wholesalers, hospitals, and pharmacies. Such end-to-end monitoring can strengthen quality control, help detect counterfeit medicines, and improve product recalls when required.

5. Conclusion

The proposed Digital Drugs Regulatory System marks one of the most ambitious reforms in India’s pharmaceutical governance architecture. If executed properly, it can create a transparent, integrated, and time-bound regulatory ecosystem that benefits both industry and public health.

Bhavin Mehta, Vice-Chairperson of Pharmexcil, has stated that the move could materially improve ease of doing business while strengthening oversight. That balance will be crucial as India seeks to position itself as a trusted global healthcare manufacturing hub.

However, success will depend on effective migration of legacy data from existing systems such as Sugam, Sugam Labs, MD Online, and ONDLS, along with smooth onboarding of all state regulators. Strong cybersecurity, user training, and continuous technical support will also be essential.

If these challenges are addressed, DDRS could become a landmark reform in India’s healthcare regulation system